Rapid Resolution of Suicidal Ideation After a Single Infusion of an N -Methyl- D -Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Objective Suicidal ideation is a medical emergency, especially when severe. Little research has been done on pharmacologic interventions that could address this problem. Ketamine, an N-methyl-D-asparate antagonist, has been reported to have antidepressant effects within hours. We examined the effects of a single dose of ketamine on suicidal ideation in subjects with treatment-resistant major depressive disorder (MDD). Method Thirty-three subjects with DSM-IV-diagnosed MDD received a single open-label infusion of ketamine (0.5 mg/kg) and were rated at baseline and at 40, 80, 120, and 230 minutes postinfusion with the Scale for Suicide Ideation (SSI), the Montgomery-Åsberg Depression Rating Scale, the Hamilton Depression Rating Scale, and the Beck Depression Inventory. The study was conducted between October 2006 and January 2009. Results Suicidal ideation scores decreased significantly on the SSI as well as on the suicide subscales of other rating instruments within 40 minutes; these decreases remained significant through the first 4 hours postinfusion (P Conclusions Suicidal ideation in the context of MDD improved within 40 minutes of a ketamine infusion and remained improved for up to 4 hours postinfusion. Future studies with ketamine in suicidal ideation are warranted due to the potential impact on public health. Trial registration clinicaltrials.gov Identifier: NCT00088699.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The rapid-acting dissociative agent ketamine, which has shown its efficacy in treating depression, is known to increase BDNF levels (37, 38).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [38]
In the citing paper
“Extensive experience with human patients has established that ketamine exerts rapid, robust antidepressant, antianhedonic, and antisuicidal actions within two hours of administration that are sustained for at least seven days in patients with major depression following a single infusion or intranasal administration [129-133].”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [131]
In the citing paper
“Recent studies report that ketamine also reduces suicide ideation, a major advance over typical antidepressants with low efficacy and delayed onset of action151,152.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [151]
In the citing paper
“Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative anesthetic ketamine induces rapid and sustained antidepressant actions in treatment-resistant patients.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [7]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationAssessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419
Linehan, M. M., Comtois, K. A., Murray, A. M., Brown, M. Z., Gallop, R. J., Heard, H. L., Korslund, K. E., Tutek, D. A., Reynolds, S. K., & Lindenboim, N. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.757 · Cited by 2,025
Assessment of Depression: The Depression Inventory
Beck, A. T., & Beamesderfer, A. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000395074 · Cited by 1,832
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Cognitive Therapy for the Prevention of Suicide Attempts: A Randomized Controlled Trial
Brown, G. K., Ten Have, T., Henriques, G. R., Xie, S. X., Hollander, J. E., & Beck, A. T. (2005) · JAMA · doi:10.1001/jama.294.5.563 · Cited by 1,045
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Cited by
Items 201–300 of 570
Zhan, Y., Zhang, B., Zhou, Y., Zheng, W., Liu, W., Wang, C., Li, H., Chen, L., Yu, L., Walter, M., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.071 · Cited by 60
Towards translational rodent models of depression
O’Leary, O. F., & Cryan, J. F. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1587-9 · Cited by 60
“Moreover, ketamine also improved depressive symptoms in treatment-resistant patients (DiazGranados et al. 2010; Zarate et al. 2006), thus suggesting ketamine not only has rapid antidepressant effects but may also be useful in treating patients who fail to respond to current antidepressant treatments.”
BackgroundTrujillo, K. A., Smith, M. L., Sullivan, B., Heller, C. Y., Garcia, C., & Bates, M. L. S. (2011) · ILAR Journal · doi:10.1093/ilar.52.3.366 · Cited by 61
Ketamine: repurposing and redefining a multifaceted drug
Potter, D. E., & Choudhury, M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.08.017 · Cited by 65
Duncan, W. C., Ballard, E. D., & Zarate, C. A. (2017) · Handbook of Experimental Pharmacology · doi:10.1007/164_2017_51 · Cited by 58
Self-citationMuscat, S.-A., Hartelius, G., Crouch, C., & Morin, K. W. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.710338 · Cited by 63
“(24) added to evidence for the efficacy of ketamine treatment by substantiating the hypothesis that ketamine has a rapid effect on the symptoms of acute suicidality.”
BackgroundPonton, E., Turecki, G., & Nagy, C. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab082 · Cited by 65
Sokolowski, M., Ben-Efraim, Y. J., Wasserman, J., & Wasserman, D. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.112 · Cited by 63
Rapid Response with Ketamine on Suicidal Cognition in Resistant Depression
Thakurta, R. G., Das, R., Bhattacharya, A. K., Saha, D., Sen, S., Singh, O. P., & Bisui, B. (2012) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.101793 · Cited by 57
Shopsin, B. (2013) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2012.00675.x · Cited by 58
Dextromethorphan as a potential rapid-acting antidepressant
Lauterbach, E. C. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.02.003 · Cited by 60
“intravenous ketamine in depression, including treatment-resistant bipolar depression in a randomized, placebo-controlled, doubleblind, crossover, add-on study [2], treatment-resistant major depression [3] and treatment-resistant major depression with suicidal ideation [4] in an open-label case series (0.”
MethodReversal of Stress-Induced Social Interaction Deficits by Buprenorphine
Browne, C. A., Falcon, E., Robinson, S. A., Berton, O., & Lucki, I. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx079 · Cited by 56
“…in symptom severity following ketamine infusion in patients with treatment-resistant depression (Zarate et al., 2006; Aan Het Rot et al., 2010; DiazGranados et al., 2010; Ibrahim et al., 2011; Murrough et al., 2013; Ionescu et al., 2016) and possibly in patients with chronic PTSD (Feder et…”
BackgroundInfluentialCharacterizing the course of suicidal ideation response to ketamine
Ballard, E. D., Yarrington, J. S., Farmer, C. A., Richards, E., Machado-Vieira, R., Kadriu, B., Niciu, M. J., Yuan, P., Park, L., & Zarate, C. A. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.07.077 · Cited by 55
“…included meeting criteria for a major depressive episode of at least moderate severity (≥ 18 on the Hamilton Depression Rating Scale (HAM-D) (Zarate et al., 2006) or≥ 20 (Diazgranados et al., 2010b; Nugent et al., 2018; Zarate et al., 2012) on the Montgomery-Asberg Depression Rating Scale (MADRS).”
InfluentialSelf-citationKetamine and esketamine in suicidal thoughts and behaviors: a systematic review
Jollant, F., Colle, R., Nguyen, T. M. L., Corruble, E., Gardier, A. M., Walter, M., Abbar, M., & Wagner, G. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231151327 · Cited by 56
“For the 12 primary RCTs, main diagnoses were various mood disorders (N = 4), bipolar disorders only (1), major depressive disorders only (4), depressed patients with various diagnoses at the emergency room (excluding psychosis; 2), and depressed patients with a newly diagnosed cancer (1).”
BackgroundKheirabadi, D., Kheirabadi, G. R., Mirlohi, Z., Tarrahi, M. J., & Norbaksh, A. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001289 · Cited by 63
“Another trial of intravenous (IV) ketamine found that its antidepressant effects lasted for at least 2 weeks.(15,16) Thus, use of IV ketamine was introduced as a treatment for depression.”
BackgroundThe rapid anti-suicidal ideation effect of ketamine: A systematic review
Hochschild, A., Grunebaum, M. F., & Mann, J. J. (2021) · Preventive Medicine · doi:10.1016/j.ypmed.2021.106524 · Cited by 55
Khan, A., Khan, S. R. F., Hobus, J., Faucett, J., Mehra, V., Giller, E. L., & Rudolph, R. L. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.06.016 · Cited by 55
“However, the data from ketamine trials (DiazGranados et al., 2010) and our trial suggest that it is possible to pick up an antisuicidal effect signal on psychological measures and behaviors in a relatively short period.”
BackgroundZheng, W., Zhou, Y., Liu, W.-J., Wang, C., Zhan, Y., Li, H.-Q., Chen, L., Li, M. D., & Ning, Y. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119827811 · Cited by 59
Niciu, M. J., Grunschel, B. D., Corlett, P. R., Pittenger, C., & Bloch, M. H. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113486718 · Cited by 52
“Ketamine is a non-competitive N-methyl-D-aspartate receptor antagonist that is Food and Drug Administration-approved in the United States for anesthesia due to its sedative effects with minimal risk of severe respiratory depression (Domino, 2010).”
BackgroundGálvez, J. F., Keser, Z., Mwangi, B., Ghouse, A. A., Fenoy, A. J., Schulz, P. E., Sanches, M., Quevedo, J., Selvaraj, S., Gajwani, P., et al. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.12.003 · Cited by 57
Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
Can, A., Hermens, D. F., Dutton, M., Gallay, C. C., Jensen, E., Jones, M., Scherman, J. K., Beaudequin, D. A., Yang, C., Schwenn, P., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01230-z · Cited by 58
Weckmann, K., Labermaier, C., Asara, J. M., Müller, M. B., & Turck, C. W. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.119 · Cited by 56
Corkery, J., Hung, W.-C., Claridge, H., Goodair, C., Copeland, C. S., & Schifano, F. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211021588 · Cited by 63
“Ketamine can swiftly reduce suicidal ideation (DiazGranados et al., 2010a; Price et al., 2014; Siegel et al., 2021).”
MethodHeal, D. J., Gosden, J., & Smith, S. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.049 · Cited by 49
“Ketamine's utility in treating disorders including treatment-resistant depression (DiazGranados et al., 2010; Murrough et al., 2013; Singh et al., 2016), PTSD (Feder et al.”
BackgroundBaghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Goodwin, G. M., Fountoulakis, K. Ν., Kasper, S. F., Leonard, B. E., Malt, U. F., Stein, D. J., et al. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0259-6 · Cited by 57
“remained up to 4-h post-infusion [128], and investigation of strategies to achieve sustained effects is required to facilitate clinical relevance to this treatment option in the future.”
BackgroundSalardini, E., Zeinoddini, A., Mohammadinejad, P., Ardakani, M. R. K., Zahraei, N., Zeinoddini, A., & Akhondzadeh, S. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.01.003 · Cited by 52
“…successful administration of other drugs with these properties such as ketamine and amantadine in MDD patients (aan het Rot et al., 2010; Ates-Alagoz and Adejare, 2013; DiazGranados et al., 2010; Duncan et al., 2013, Ibrahim et al., 2012; Maeng and Zarate, 2007; Murrough et al., 2013; Owen, 2012).”
The role of the excitation:inhibition functional balance in the mPFC in the onset of antidepressants
Yin, Y., Wang, Y., Liu, W., Yao, J.-Q., Yuan, J., Li, Z.-H., Ran, Y., Zhang, L., & Li, Y. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108573 · Cited by 54
Does Ketamine Have Anti-Suicidal Properties? Current Status and Future Directions
Price, R. B., & Mathew, S. J. (2015) · CNS Drugs · doi:10.1007/s40263-015-0232-4 · Cited by 49
“Similar results were obtained in a sample of 33 TRD patients following a single infusion [14] at the same dose as in the Price et al.”
Age dependence of the rapid antidepressant and synaptic effects of acute NMDA receptor blockade
Nosyreva, E., Autry, A. E., Kavalali, E. T., & Monteggia, L. M. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00094 · Cited by 51
“ORIGINAL RESEARCH ARTICLE published: 01 December 2014 doi: 10.3389/fnmol.2014.00094 Age dependence of the rapid antidepressant and synaptic effects of acute NMDA receptor blockade”
BackgroundInfluentialEsterlis, I., Holmes, S. E., Sharma, P., Krystal, J. H., & DeLorenzo, C. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.025 · Cited by 50
Vásquez, C. E., Riener, R. M., Reynolds, E., & Britton, G. B. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.09.007 · Cited by 52
Investigational NMDA receptor modulators for depression
Szewczyk, B., Pałucha-Poniewiera, A., Poleszak, E., Pilc, A., & Nowak, G. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.638916 · Cited by 49
“Rapid antidepressant efficacy of a ketamine infusion was also found in resistant depressive patients with a confirmed family history of alcohol dependence [36]; in patients with suicidal ideation in the context of major depression [37] and in treatment-resistant bipolar depression [38].”
BackgroundMaltbie, E. A., Gopinath, K., & Howell, L. L. (2017) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000354 · Cited by 94
“Indeed, the rapid onset of improvement in suicidal ideation induced by ketamine, reported to emerge as quickly as 40min after infusion (DiazGranados et al., 2010), provides a major advantage for treating this psychiatric emergency as other effective treatments are slower acting (Reinstatler and Youssef, 2015).”
BackgroundToki, H., Ichikawa, T., Mizuno‐Yasuhira, A., & Yamaguchi, J.-I. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.09.033 · Cited by 55
NMDA antagonists under investigation for the treatment of major depressive disorder
Pochwat, B., Pałucha-Poniewiera, A., Szewczyk, B., Pilc, A., & Nowak, G. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.918951 · Cited by 47
“Importantly, in about 50 -80% of patients, all depressive symptoms and even suicidal ideation tend to weaken after a single infusion of ketamine [26,27].”
BackgroundRole of the mTOR signaling pathway in the rapid antidepressant action of ketamine
Hashimoto, K. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.176 · Cited by 47
Toxoplasma gondii, Suicidal Behavior, and Intermediate Phenotypes for Suicidal Behavior
Postolache, T. T., Wadhawan, A., Rujescu, D., Hoisington, A. J., Dagdag, A., Baca‐García, E., Lowry, C. A., Okusaga, O. O., & Brenner, L. A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.665682 · Cited by 51
“gondii infection may represent, in the future, a more targeted application of ketamine that shows a robust anti-suicidal effect within minutes or hours after intravenous administration (204, 205).”
BackgroundLi, S., Luo, X., Hua, D., Wang, Y., Zhan, G., Huang, N., Jiang, R., Yang, L., Zhu, B., Yuan, X., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01702 · Cited by 49
Liu, W., Zhou, Y., Zheng, W., Wang, C., Zhan, Y., Lan, X., Zhang, B., Li, H., Chen, L., & Ning, Y. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.08.012 · Cited by 45
Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review
S Correia-Melo, F., C Argolo, F., Araújo-de-Freitas, L., Carneiro Gomes Leal, G., Kapczinski, F., L Lacerda, A., & C Quarantini, L. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s135623 · Cited by 43
Patton, M. S., Lodge, D. J., Morilak, D. A., & Girotti, M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.236 · Cited by 44
“Ketamine has garnered considerable interest as a rapidly acting antidepressant, with efficacy in treatment resistant patients (DiazGranados et al, 2010).”
BackgroundCamargo, A., Pazini, F. L., Rosa, J. M., Wolin, I. A. V., Moretti, M., da Rosa, P. B., Neis, V. B., & Rodrigues, A. L. S. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.05.017 · Cited by 45
Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
de Sousa, R. T., V. Zanetti, M., R. Brunoni, A., & Machado-Vieira, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630173522 · Cited by 43
Self-citationAmidfar, M., Réus, G. Z., Quevedo, J., & Kim, Y.-K. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.023 · Cited by 43
Ketamine and suicidal ideation in depression: Jumping the gun?
Rajkumar, R., Fam, J., Yeo, E. Y. M., & Dawe, G. S. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.05.003 · Cited by 46
Vai, B., Poletti, S., Radaelli, D., Dallaspezia, S., Bulgarelli, C., Locatelli, C., Bollettini, I., Falini, A., Colombo, C., Smeraldi, E., et al. (2015) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2015.07.015 · Cited by 43
Depression in Medically Ill Patients
Rackley, S. J., & Bostwick, J. M. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.001 · Cited by 44
Memantine and Catatonia: A Case Report and Literature Review
Obregon, D. F., Velasco, R. M., Wuerz, T. P., Catalano, M. C., Catalano, G., & Kahn, D. A. (2011) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000400268.60537.5e · Cited by 50
Wilkinson, S. T., & Sanacora, G. (2016) · Depression and Anxiety · doi:10.1002/da.22498 · Cited by 39
“Åsberg Depression Rating Scale [MADRS], Hamilton Depression Rating Scale [HDRS], Beck Depression Inventory [BDI], and Beck Scale for SI [SSI]).[27] Pre–post effect sizes were largest at 40 min (d = 1.”
MethodOkada, M., Fukuyama, K., Okubo, R., Shiroyama, T., & Ueda, Y. (2019) · Pharmaceuticals · doi:10.3390/ph12040149 · Cited by 41
“5 mg/kg) of intravenous ketamine exert rapid and profound antidepressant effects with reduced suicidal ideation within hours to days of administration [38,39].”
Ketamine: The final frontier or another depressing end?
Sial, O. K., Parise, E. M., Parise, L. F., Gnecco, T., & Bolaños‐Guzmán, C. A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112508 · Cited by 45
Star-D: lessons learned and future implications
Rush, A. J. (2011) · Depression and Anxiety · doi:10.1002/da.20841 · Cited by 43
Plasticity of synapses and reward circuit function in the genesis and treatment of depression
Thompson, S. M. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01422-1 · Cited by 40
Suicidality and Activation of the Kynurenine Pathway of Tryptophan Metabolism
Bryleva, E. Y., & Brundin, L. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_5 · Cited by 43
Traumatic Brain Injury and Suicidal Behavior: A Review
Wadhawan, A., Stiller, J. W., Potocki, E., Okusaga, O. O., Dagdag, A., Lowry, C. A., Benros, M. E., & Postolache, T. T. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181055 · Cited by 41
“…have reported that patients with major depression who had received sub-anesthetic doses of intravenous ketamine, which has antagonistic activity on NMDA receptors, had rapid improvement in their symptoms of depression [328, 329] and suicidal ideation in the setting of major depression [330].”
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Mathews, D. C., Richards, E. M., & Zarate, C. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.01.038 · Cited by 39
“In our randomized, controlled, crossover studies in major depressive disorder (2) and bipolar depression (4,8), 3 of 44 (7%) subjects who received placebo and 5 of 52 (10%) subjects who received ketamine had maniclike worsening (7).”
BackgroundSelf-citationNeurobiological aspects of suicide and suicide attempts in bipolar disorder
Mathews, D., Richards, E., Niciu, M., Ionescu, D., Rasimas, J., & Zarate, C. (2013) · Translational Neuroscience · doi:10.2478/s13380-013-0120-7 · Cited by 39
Self-citationOstacher, M. J., Nierenberg, A. A., Rabideau, D., Reilly-Harrington, N. A., Sylvia, L. G., Gold, A. K., Shesler, L. W., Ketter, T. A., Bowden, C. L., Calabrese, J. R., et al. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.10.004 · Cited by 40
“…(Beck et al., 1979; Montgomery and Asberg, 1979; Rush et al., 2003) and MADRS, YMRS, CARS-M, QIDS, LIFE-RIFT, and Q-LES-QSF to assess concurrent validity (DiazGranados et al., 2010; Morris et al., 2010; Ponizovsky et al., 2003; Trivedi et al., 2011a; Umamaheswari et al., 2014; Weiss et al., 2005).”
MethodSinyor, M., Williams, M., Belo, S., Orser, B., Vincent, M., Mah, L., Zarate, C., Castel, S., Levitt, A. J., & Schaffer, A. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.07.073 · Cited by 36
Self-citationInpatient suicide in psychiatric settings: Evaluation of current prevention measures
Chammas, F., Januel, D., & Bouaziz, N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.997974 · Cited by 38
Methoxetamine: From drug of abuse to rapid-acting antidepressant
Coppola, M., & Mondola, R. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.07.002 · Cited by 41
Ardalan, M., Wegener, G., Polsinelli, B., Madsen, T. M., & Nyengaard, J. R. (2016) · Hippocampus · doi:10.1002/hipo.22617 · Cited by 38
“An important concern related to MDD is the suicidal ideation as an emergency condition which requires rapid-acting antidepressant drugs (DiazGranados et al., 2010), while a prominent limitation of conventional antidepressant treatment is the several-week interval between the administration of drugs and the adequate cl…”
BackgroundSex- and dose-dependent abuse liability of repeated subanesthetic ketamine in rats
Schoepfer, K. J., Strong, C. E., Saland, S. K., Wright, K. N., & Kabbaj, M. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.10.021 · Cited by 39
Astroglial Connexin43 as a Potential Target for a Mood Stabiliser
Okada, M., Oka, T., Nakamoto, M., Fukuyama, K., & Shiroyama, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010339 · Cited by 38
Current Status of Ketamine and Related Compounds for Depression: (ASCP Corner)
Mathews, D. C., & Zarate, Jr. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13ac08382 · Cited by 35
Self-citationKetamine as Antidepressant? Current State and Future Perspectives
Hasselmann, H. (2013) · Current Neuropharmacology · doi:10.2174/1570159x113119990043 · Cited by 43
Hyperforin Potentiates Antidepressant-Like Activity of Lanicemine in Mice
Pochwat, B., Szewczyk, B., Kotarska, K., Rafało-Ulińska, A., Siwiec, M., Sowa, J. E., Tokarski, K., Siwek, A., Bouron, A., Friedland, K., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00456 · Cited by 42
Shah, A., Carreno, F. R., & Frazer, A. (2014) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2014.12.2.83 · Cited by 35
Niciu, M. J., Henter, I. D., Sanacora, G., & Zarate, C. A. (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.829585 · Cited by 40
“Interestingly, ketamine decreases suicidality in high-risk populations (Price et al. 2009; DiazGranados et al. 2010b), including in the emergency setting (Larkin et al. 2011), but it remains to be seen if ketamine or other glutamatergic modulators have anti-suicidal properties in this high risk…”
BackgroundSelf-citationPałucha-Poniewiera, A. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.02.011 · Cited by 36
Okusaga, O. O., Duncan, E., LANGENBERG, P. W., Brundin, L., Fuchs, D., Groer, M. E., Giegling, I., Stearns‐Yoder, K. A., Hartmann, A. M., Konte, B., et al. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.10.002 · Cited by 37
Ketamine in Bipolar Disorder: A Review
Wilkowska, A., Szałach, Ł. P., & Cubała, W. J. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s282208 · Cited by 35
“open-label studies found that a single intravenous ketamine infusion significantly reduced suicidal ideation in subjects with treatment-resistant depression.(32,33)”
BackgroundFraga, D. B., Camargo, A., Olescowicz, G., Padilha, D. A., Mina, F., Budni, J., Brocardo, P. S., & Rodrigues, A. L. S. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109476 · Cited by 36
Ju, L.-S., Yang, J., Zhu, T., Liu, P., & Yang, J. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03838-x · Cited by 36
Lascelles, K. M., Marzano, L., Brand, F., Trueman, H., McShane, R. H., & Hawton, K. E. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-029108 · Cited by 36
“Our findings, and those of others,12 18 suggest that there should be more focus on investigating the mechanisms involved in beneficial effects of ketamine on SI.”
BackgroundInfluentialAverill, L. A., Averill, C. L., Gueorguieva, R., Fouda, S., Sherif, M., Ahn, K.-H., Ranganathan, M., D'Souza, D. C., Southwick, S. M., Sanacora, G., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.01.104 · Cited by 33
Digital Suicide Prevention: Can Technology Become a Game-changer?
Vahabzadeh, A. B. N., Sahin, N. T., & Kalali, A. H. (2016) · Europe PMC (PubMed Central) · Cited by 33
Acevedo-Diaz, E. E., Cavanaugh, G. W., Greenstein, D. K., Kraus, C., Kadriu, B., Park, L., & Zarate, C. A. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.06.012 · Cited by 36
Self-citationHas psychiatry tamed the “ketamine tiger?” Considerations on its use for depression and anxiety
Rasmussen, K. G. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.01.002 · Cited by 32
“…studies documenting rapid antidepressant response, generally with return to baseline severity within days to two weeks or so of the infusion (Diazgranados et al., 2010b; Duncan et al., 2013; Ibrahim et al., 2011, 2012; Mathew et al., 2010; Phelps et al., 2009; Salvadore et al., 2010;…”
BackgroundInfluentialCanuso, C. M., Singh, J. B., Fedgchin, M. M., Alphs, L. D., Lane, R., Lim, P., Pinter, C., Hough, D. W., Sanacora, G., Manji, H. K., et al. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.17105 · Cited by 42
Okada, M., Kawano, Y., Fukuyama, K., Motomura, E., & Shiroyama, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217951 · Cited by 32
Agmatine as a novel candidate for rapid-onset antidepressant response
Valverde, A. P., Camargo, A., & Rodrigues, A. L. S. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i11.981 · Cited by 33
Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches
Jurdi, R. K. A., Swann, A. C., & Mathew, S. J. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0614-9 · Cited by 36
Glutamate system as target for development of novel antidepressants
Catena-Dell’Osso, M., Fagiolini, A. M., Rotella, F., Baroni, S., & Marazziti, D. (2013) · CNS Spectrums · doi:10.1017/s1092852912000971 · Cited by 33
“Similarly, in another study, which was carried out in 33 MDD patients, a single ketamine infusion was able to dramatically reduce suicidal ideation within 40 minutes, and the improvement lasted for up to 4 hours post-infusion.(76) In a more recent study, 25 bipolar depressed subjects taking mood stabilizing drugs were…”
ResultInvestigational drugs for treating major depressive disorder
Dhir, A. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1267727 · Cited by 32
Bai, L., Hou, Y., Zhu, M., Bao, H., Nie, J., Zhang, G. Y., Shan, L., Yao, Y., Du, K., Yang, H., et al. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv112 · Cited by 34
“…B) The expression levels of synaptic GluR2 were not increased in the PFC and HIP after 45-minute or 5-day treatments with 3’-dA. depression (Berman et al., 2000; Zarate et al., 2006; Price et al., 2009) or bipolar depression (DiazGranados et al., 2010; Zarate et al., 2012; Krystal et al., 2013).”
BackgroundA Novel Application of Ketamine for Improving Perioperative Sleep Disturbances
Song, B., & Zhu, J. (2021) · Nature and Science of Sleep · doi:10.2147/nss.s341161 · Cited by 33
Poleszak, E., Stasiuk, W., Szopa, A., Wyska, E., Serefko, A., Oniszczuk, A., Wośko, S., Świąder, K., & Właź, P. (2016) · Metabolic Brain Disease · doi:10.1007/s11011-016-9810-5 · Cited by 33
“Therefore, inhibition of the NMDA receptor complex may provide new possibilities in the treatment of mental disorders (e.g., DiazGranados et al. 2010; Gosek et al. 2012; Maeng and Zarate 2007; Poleszak et al. 2014; Price et al. 2009).”
BackgroundKetamine steps out of the darkness
Malinow, R. (2016) · Nature · doi:10.1038/nature17897 · Cited by 31
Yang, C., Li, W.-Y., Yu, H.-Y., Gao, Z.-Q., Liu, X.-L., Zhou, Z.-Q., & Yang, J.-J. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/175619 · Cited by 29
Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants
Chaki, S., & Fukumoto, K. (2015) · Pharmaceuticals · doi:10.3390/ph8030590 · Cited by 35
“To date, several studies have replicated the rapid and sustained antidepressant effects of ketamine [1,2,4], including a two-site, parallel-arm, randomized controlled trial using an active placebo control condition, the anesthetic benzodiazepine midazolam, to optimize blinding and to mitigate the influence of nonspeci…”
BackgroundMachado‐Vieira, R., & Zarate, C. A. (2011) · Depression and Anxiety · doi:10.1002/da.20800 · Cited by 30
Self-citationGass, N., Becker, R., Sack, M., Schwarz, A. J., Reinwald, J., Cosa‐Linan, A., Zheng, L., von Hohenberg, C. C., Inta, D., Meyer‐Lindenberg, A., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4823-2 · Cited by 31
“after administration, yet dissociative side effects are also observed in the first 2 h after administration (Zarate et al. 2006; DiazGranados et al. 2010).”
BackgroundCamargo, A., Dalmagro, A. P., de Souza, M. M., Zeni, A. L. B., & Rodrigues, A. L. S. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113459 · Cited by 29
“Ketamine can relieve depressive symptoms within hours after a single dose and its effects can last up to 2 weeks, even in treatment-resistant patients with suicidal ideation (DiazGranados et al., 2010; Price et al., 2009; Zarate et al., 2006).”
BackgroundDNA methylation in stress and depression: from biomarker to therapeutics
Sales, A. J., Guimarães, F. S., & Joca, S. R. L. (2021) · Acta Neuropsychiatrica · doi:10.1017/neu.2021.18 · Cited by 30
Holubová, K., Nekovářová, T., Pistovčáková, J., Šulcová, A., Stuchlík, A. (., & Valeš, K. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00130 · Cited by 29
“But several studies demonstrate antidepressant properties of a single administration of ketamine – the non-competitive N -methyl-d-aspartic acid receptor (NMDAR) antagonist (Berman et al., 2000; Zarate et al., 2006, 2012; Diazgranados et al., 2010).”
BackgroundOpler, L. A., Opler, M. G. A., & Arnsten, A. F. T. (2016) · CNS Spectrums · doi:10.1017/s1092852914000686 · Cited by 28
“DiazGranados et al 10 looked at suicidality in 33 patients with MDD receiving a single open-label infusion of ketamine.”
BackgroundMood Therapeutics: Novel Pharmacological Approaches for Treating Depression
Henter, I. D., SOUSA, R. T. D., Gold, P. W., Brunoni, A. R., Zarate, C. A., & Machado‐Vieira, R. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1253472 · Cited by 31
“5 mg/kg) reduced measures of suicidal ideation in 33 patients with treatment-resistant MDD, an effect that was maintained for up to 4 h postinfusion [35].”
BackgroundSelf-citationZhu, J., Hawkins, E., Phillips, K., & Deshpande, L. S. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17134710 · Cited by 27
“KET’s rapid onset is considered to be ideal in depression patients with risk of suicide [46], compared to traditional antidepressants which have delayed onset of therapeutic effects, and KET infusions have been reported to decrease suicidal ideations within 24 h [47].”
BackgroundPradhan, B., Parikh, T., Makani, R. D., & Sahoo, M. (2015) · Depression Research and Treatment · doi:10.1155/2015/842817 · Cited by 32
“One randomized controlled trial that used ketamine infusion in 33 such patients found rapid reversal of suicidality in them [25].”
BackgroundInfluential
Metadata
- Authors
- DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A.
- Affiliations
- National Institute of Mental Health (US)
- National Institutes of Health (US)
- Corresponding author
- Zarate, Carlos A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-07-13
- Volume
- 71
- Issue
- 12
- Pages
- 1605-1611
- ISSN
- 0160-6689 (ISSN-L)
- PMC
- PMC3012738
- OpenAlex
- W2103255996
- Cited by
- 564
- References
- 41
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 22 · 2023: 21 · 2022: 41 · 2021: 41 · 2020: 39 · 2019: 35 · 2018: 49 · 2017: 33 · 2016: 51 · 2015: 59 · 2014: 52 · 2013: 40 · 2012: 30
- FWCI
- 23.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (Z99 MH999999)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- suicidal ideation, ketamine, NMDA receptor antagonists, rapid antidepressant effects, single-dose infusion, hopelessness, anxiety, depression
- MeSH terms
- Adult, Antidepressive Agents, Depression, Depressive Disorder, Major, Major Depressive Disorder, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Psychiatric Status Rating Scales, Time Factors, N-Methylaspartate, Treatment Outcome, Excitatory Amino Acid Antagonists, Diagnostic and Statistical Manual of Mental Disorders, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.